
IGC Pharma Reports IGC-M3’s In Vitro Efficacy Against Alzheimer’s – Targeting key Drivers of Disease Progression
POTOMAC, MARYLAND – August 05, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging AI to develop innovative treatments for Alzheimer’s and